The 10 remaining mysteries of inflammatory bowel disease

Gut

Volumn 57, Issue 4, 2008, Pages 429-433

  Colombel, Jean Frédéric ^a   Watson, Alastair J M ^b   Neurath, Markus F ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CARCINOGEN; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

APPENDICITIS; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL STRAIN; CELL PROLIFERATION; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA DAMAGE; ENTERITIS; ENVIRONMENTAL EXPOSURE; ESCHERICHIA COLI; FAT INTAKE; GASTROINTESTINAL TRACT; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INTESTINE MUCOSA; LISTERIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MUCOSA INFLAMMATION; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; T LYMPHOCYTE; ULCERATIVE COLITIS; UNITED STATES; YERSINIA; PATHOLOGY;

APPENDICITIS; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS; SMOKING;

EID: 41149092188     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.122192     Document Type: Review

References (94)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
2. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
3. Duerr RH, Barmada MM, Zhang L, et al. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet 2002;11:2599-606.
4. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2.
5. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000;11:191-196.
6. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3:394-400.
7. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 1996;63:741-5.
8. Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005;11:154-63.
9. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022- 3.
10. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007;449:804-10.
11. Hugot JP, Alberti C, Berrebi D, et al. Crohn's disease: the cold chain hypothesis. Lancet 2003;362:2012-5.
12. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007;56:610-2.
13. Peyrin-Biroulet L, Neut C, Colombel JF. Antimycobacterial therapy in Crohn's disease: game over? Gastroenterology 2007;132:2594-8.
14. Garn H, Renz H. Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology 2007;212:441-52.
15. Di Giacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 2005;174:3237-46.
16. Card T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut 2004;53:246-50.
17. Andersson RE, Olaison G, Tysk C, et al. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001;344:808- 14.
18. Andersson RE. Inverse association between appendectomy and ulcerative colitis. Surgery 2002;131:472; author reply 472-3.
19. Kaplan GG, Pedersen BV, Andersson RE, et al. The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut 2007.
20. Kawachiya T, Oshitani N, Jinno Y, et al. Significance of increased proliferation of immature plasma cells in the appendix of patients with ulcerative colitis. Int J Mol Med 2005;15:417-23.
21. Fujihashi K, McGhee JR, Lue C, et al. Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis. J Clin Invest 1991;88:248-52.
22. Mizoguchi A, Mizoguchi E, Chiba C, et al. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996;184:707-15.
23. Sakamaki S, Takayanagi N, Yoshizaki N, et al. Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells. Gut 2000;47:236-41.
24. Kovvali G, Das KM. Molecular mimicry may contribute to pathogenesis of ulcerative colitis. FEBS Lett 2005;579:2261-6.
25. Mudter J, Neurath MF. II-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007;13:1016-23.
26. Ruber M, Berg A, Ekerfelt C, et al. Different cytokine profiles in patients with a history of gangrenous or phlegmonous appendicitis. Clin Exp Immunol 2006;143:117-24.
27. Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking - a review. Am J Gastroenterol 1998;93:144-9.
28. Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: is it disease or organ specific? World J Gastroenterol 2007;13:2150-2.
29. King TE, Jr., Savici D, Campbell PA. Phagocytosis and killing of Listeria monocytogenes by alveolar macrophages: smokers versus nonsmokers. J Infect Dis 1988;158:1309-16.
30. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;2:1057-62.
31. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125:58-69.
32. Watson AJ. In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. Gut 2007;56:461-3.
33. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116:557-65.
34. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 2004;279:40209-19.
35. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
36. Hegazi RA, Rao KN, Mayle A, et al. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med 2005;202:1703-13.
37. Sadis C, Teske G, Stokman G, et al. Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PLoS ONE 2007;2:e469.
38. Finnie IA, Campbell BJ, Taylor BA, et al. Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Clin Sci (Lond) 1996;91:359-64.
39. Louvet B, Buisine MP, Desreumaux P, et al. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis 1999;5:174-81.
40. Geboes K. Is histology useful for the assessment of the efficacy of immunosuppressive agents in IBD and if so, how should it be applied? Acta Gastroenterol Belg 2004;67:285-9.
41. Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol 2004;57:1233-44.
42. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-21.
43. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002;8:567-73.
44. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
45. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
46. Schmid M, Fellermann K, Fritz P, et al. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007;81:907-15.
47. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004;127:80-93.
48. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131:33-45.
49. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311-9.
50. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
51. Valdez R, Appelman HD, Bronner MP, et al. Diffuse duodenitis associated with ulcerative colitis. Am J Surg Pathol 2000;24:1407-13.
52. Sharif F, McDermott M, Dillon M, et al. Focally enhanced gastritis in children with Crohn's disease and ulcerative colitis. Am J Gastroenterol 2002;97:1415-20.
53. Achkar JP, Dassopoulos T, Silverberg MS, et al. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol 2006;101:572-80.
54. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005;206:296-305.
55. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6.
56. Geboes K. Crohn's disease, ulcerative colitis or indeterminate colitis - how important is it to differentiate? Acta Gastroenterol Belg 2001;64:197-200.
57. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-61.
58. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005;128:891- 906.
59. Wehkamp J, Wang G, Kubler I, et al. The Paneth cell α-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol 2007;179:3109-18.
60. Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology 2005;129:1845-53.
61. Crohn B, Ginsberg L, Oppenheimer G. Regional ileitis: a clinical and pathological entity. JAMA 1932;99:1323-1329.
62. Mottet N. Intestinal histopathology of regional enteritis. In: Mottet N, ed. Histopathologic spectrum of regional enteritis and ulcerative colitis. Philadelphia: Saunders, 1971:63-107.
63. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007;56:577-83.
64. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73-81.
65. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006;55:1561-7.
66. Maconi G, Parente F, Bollani S, et al. Factors affecting splanchnic haemodynamics in Crohn's disease: a prospective controlled study using Doppler ultrasound. Gut 1998;43:645-50.
67. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006;130:2060-73.
68. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007;56:855-62.
69. Van Kruiningen H, Colombel JF. The forgotten role of lymphangitis in Crohn's disease. Gut 2007;57:1-4.
70. Mooney EE, Walker J, Hourihane DO. Relation of granulomas to lymphatic vessels in Crohn's disease. J Clin Pathol 1995;48:335-8.
71. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-4.
72. Israeli E, Grotto I, Gilburd B, et al. Anti- Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6.
73. Van Kruiningen HJ, Ganley LM, Freda BJ. The role of Peyer's patches in the age-related incidence of Crohn's disease. J Clin Gastroenterol 1997;25:470-5.
74. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006;12:551-7.
75. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
76. Sonnenberg A, Jacobsen SJ, Wasserman IH. Periodicity of hospital admissions for inflammatory bowel disease. Am J Gastroenterol 1994;89:847-51.
77. Gebhard RL, Greenberg HB, Singh N, et al. Acute viral enteritis and exacerbations of inflammatory bowel disease. Gastroenterology 1982;83:1207-9.
78. Kangro HO, Chong SK, Hardiman A, et al. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990;98:549-53.
79. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005;54:1481- 91.
80. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992;33:331-5.
81. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
82. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-46.
83. Cameron JL, Hamilton SR, Coleman J, et al. Patterns of ileal recurrence in Crohn's disease. A prospective randomized study. Ann Surg 1992;215:546-51; discussion 551-2.
84. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
85. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-84.
86. Tonelli P. [New developments in Crohn's disease: unravelling the mystery of its etiopathogenesis and its reinstatement as a surgically treatable condition. Part 3: the rational principles of surgical therapy]. Chir Ital 2000;52:335-42.
87. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
88. Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007;117:1566-74.
89. Orchard TR, Jewell DA. Extraintestinal manifestations: skin, joints and mucocutaneous manifestations. In: Sartor R, Sandborn WJ, eds. Kirsner's inflammatory bowel diseases. Edinburgh: Saunders, 2004:658-72.
90. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123:714-8.
91. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-8.
92. Angulo P, Lindor K. Primary sclerosing cholangitis. In: Sartor RB, Sandborn WJ, eds. Kirsner's inflammatory bowel diseases. Edinburgh: Saunders, 2004:647-657.
93. Grant AJ, Lalor PF, Salmi M, et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359:150-7.
94. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.